
Get insights into the CEO Rating Score of Affimed N.V.. See CEO Rating Score by Department, Gender, Ethnicity and more.
Not enough ratings to compare against similar size companies on Comparably.
1st place versus 3 competitors rated on Comparably
Dr. Adi Hoess, M.D., Ph.D., has been the Chief Executive Officer of Affimed N.V. since September 2011 and serves as its Managing Director and Member of Management Board. Dr. Hoess served as Chief Commercial Development Officer of Jerini AG from January 2003 to October 2008. Dr. Hoess served as the Chief Business Officer of Jerini AG and served as its Member of the Management Board until October 2008. He joined MorphoSys in 1993 where he served as a Director of Business Development since 1997 and then Vice President of Licensing/ Business Development. He was responsible for the closing of over 20 collaboration and licensing agreements at MorphoSys. In January 2001, Dr. Hoess joined Carl Zeiss Jena as Vice President and General Manager of the Molecular Medicine Business Division. He served as a Director of Amphivena Therapeutics Inc., since July 2013. He won a 5-year post-doctoral fellowship from the German Cancer Research Center for work at the Dana-Farber Cancer Institute at Harvard Medical School and work at the Medical Research Institute of the Technical University of Munich. During this time, he was the first person to determine the structure and function of an endotoxin-neutralizing protein. In March 1997, he received an M.D. degree. Dr. Hoess studied biochemistry at the Ludwig Maximilian University in Munich, graduating in 1987. He completed his Ph.D. in 1990.
The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Affimed N.V..
Based on 12 ratings, Adi Hoess M.D., Ph.D. ranks right above Clinigen Group's CEO, Shaun Chilton.
Affimed N.V. CEO is highly regarded by employees with 1 to 3 Years experience, Male employees, and Caucasian employees. However, employees with 3 to 6 Years experience have a less favorable view of the CEO and believe there is room for improvement. Overall, the CEO score has remained stable over the last 90 days.
Not enough ratings to compare against similar size companies on Comparably.
